How I use hydroxyurea to treat young patients with sickle cell anemia.
about
Blood transfusion for preventing primary and secondary stroke in people with sickle cell diseaseNovel insights in the management of sickle cell disease in childhoodMolecular pathophysiology of priapism: emerging targetsA biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical careChanges in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones.Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemiaMen with Sickle Cell Anemia and Priapism Exhibit Increased Hemolytic Rate, Decreased Red Blood Cell Deformability and Increased Red Blood Cell Aggregate StrengthHydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectinPatient-specific blood rheology in sickle-cell anaemia.Patient-specific modeling of individual sickle cell behavior under transient hypoxia.Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia.In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technologyHydroxyurea treatment of children with hemoglobin SC disease.Effects of hydroxyurea treatment for patients with hemoglobin SC disease.Burden of diagnostic radiation exposure in children with sickle cell disease.Hydroxyurea is associated with lower costs of care of young children with sickle cell anemiaDifferential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events.Is sickle cell anemia a neglected tropical disease?Update on fetal hemoglobin gene regulation in hemoglobinopathiesTreatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasmsManagement of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa).Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposureHydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Massive accidental overdose of hydroxyurea in a young child with sickle cell anemiaPharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis.Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosisStroke With Transfusions Changing to Hydroxyurea (SWiTCH).Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.Effect of Age on Blood Rheology in Sickle Cell Anaemia and Sickle Cell Haemoglobin C Disease: A Cross-Sectional StudyHemoglobin sickle cell disease complications: a clinical study of 179 casesFrom infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia.Hydroxycarbamide: clinical aspects.Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
P2860
Q24202463-6D8D2C3A-CB24-4683-9618-89A8DE83EFF2Q26767015-CEB150C0-0734-4B0F-8F05-4166F46FB055Q27010069-3FEE8B60-EEAE-4981-A5E1-FEFBDAD55CF5Q27024148-95EF4FB4-2FC7-481A-B7FC-B4C4B48C3338Q27318600-80AFD879-6FEA-43DF-92FD-5B961CC6CA1FQ28544643-EC53C11A-66B8-4349-A47F-3D45E18B6D61Q28551776-3EB59327-BCD3-4967-9EF1-B5B5679D738DQ30506249-EFA2C6A2-B189-4B08-8094-45AE2E0E6FB0Q30691183-0710C473-FB0E-4F70-B5B7-B418E44355C1Q30843061-29793DAF-D87B-4FAC-9795-4240FB021E66Q31141526-1BE4964E-B41A-44CF-AF9C-A233E774AC2CQ33398661-94C8B530-323B-475A-8182-BABBC4A3C501Q33403128-E53E1972-2730-4D85-BD00-9C441B9EC02AQ33427950-090A1045-68F4-4446-8536-525012912AB3Q33560812-7F29F2A1-34C9-4932-A58F-DEF6C82DF432Q33819687-1378A1CB-8291-4B4A-B5FC-BA32720498E9Q34750534-A76DE27F-4AB5-407D-A7E4-C9ECF2574BE3Q34764415-4B186E1B-03B7-49FF-A21D-9A47D5BCBB51Q34973945-3B3DC0B1-73F4-4AAB-8201-FFC61C0869C8Q35023473-B2F1BEEA-6132-4A0D-9DA2-377D69658310Q35034032-E3E5AA61-5E2A-48FB-9CF9-07F33C52FC39Q35036897-54C45A15-800B-42D3-B830-770D74F3A670Q35097294-2B7A91A9-36F2-4EA6-98A2-7B275380F61AQ35209572-ECC7FD3B-1A9B-48C4-85F1-B145C69819F9Q35234959-59534FEA-1EB9-4AD2-BD2C-FC35CF9AADF4Q35353627-B1680864-D174-478E-A701-A6BD0535A1ACQ35525659-30C4C014-1A6D-4F49-B48F-BAF0F021ED08Q35553378-77474F3A-0B9A-4329-8F95-61E17744325EQ35751797-3C2ED5DE-99AC-4807-B30B-571352B1FE7DQ35843842-F1057F1F-4E9C-4D3A-AFC1-FAEC2F39DAABQ35881838-CFD4B069-3923-405D-911C-DE3A10EF444FQ35951578-F95B8ADF-64CA-4472-8E14-1030D023FC34Q35953361-4B120DA4-9A35-4239-94A5-5B0A032442C1Q36028317-0DFDC984-AC1A-4ECB-9B41-2C1AE75D000BQ36063983-3852EDEC-D9C1-4C48-ADA8-C27B465F25F2Q36132987-56D23F60-A390-4D70-91D9-D53BCF446929Q36154109-7D7387D4-9AD8-411C-8F81-B89CD1902CC8Q36155283-4C38872B-1BB0-4044-BD64-3DDFF8621BC0Q36239553-846C62D7-31C6-4265-997D-B20E002F5FB2Q36251052-D5C5C2BE-9E45-4255-8AE2-1638793018D0
P2860
How I use hydroxyurea to treat young patients with sickle cell anemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
How I use hydroxyurea to treat young patients with sickle cell anemia.
@ast
How I use hydroxyurea to treat young patients with sickle cell anemia.
@en
type
label
How I use hydroxyurea to treat young patients with sickle cell anemia.
@ast
How I use hydroxyurea to treat young patients with sickle cell anemia.
@en
prefLabel
How I use hydroxyurea to treat young patients with sickle cell anemia.
@ast
How I use hydroxyurea to treat young patients with sickle cell anemia.
@en
P2860
P1433
P1476
How I use hydroxyurea to treat young patients with sickle cell anemia.
@en
P2093
Russell E Ware
P2860
P304
P356
10.1182/BLOOD-2009-04-146852
P407
P577
2010-03-11T00:00:00Z